Clinical Trial Update: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating crizotinib in combination with a VEGF inhibitor for advanced solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell, Glioblastoma | Phase 1 | Status: WITHDRAWN